Androgen receptors in breast cancer

Androgen receptor assays have been performed on 1371 specimens of histologically confirmed primary and recurrent breast cancer. Forty‐two patients who had received tamoxifen as treatment for advanced disease were assessed for objective response. Another 42 patients who had received chemotherapy were similarly studied. Patients with androgen receptor‐negative tumors had a significantly poorer response rate to hormone therapy than those with receptor‐positive tumors (P < 0.05). This clinical correlation is supported by survival data of 1181 patients with primary breast cancer which showed that patients with androgen receptor‐negative tumors had a highly significant trend toward shorter overall survival than those with receptor‐positive tumors (P < 0.001). Androgen receptor data added significantly to the information provided by estrogen receptor data both in terms of response to hormone treatment and survival.

[1]  R. Bryan,et al.  THE PROGNOSTIC VALUE OF OESTROGEN RECEPTORS IN BREAST CANCER , 1984 .

[2]  R. Bryan,et al.  Oestradiol receptor values in breast cancer and response of metastases to therapy. , 1984, The Australian and New Zealand journal of surgery.

[3]  G. Rennie,et al.  Hormone‐receptor assays in breast cancer , 1983, The Medical journal of Australia.

[4]  K. Seibert,et al.  Hormone receptors in breast cancer , 1982 .

[5]  R. Blamey,et al.  QUANTITATIVE OESTRADIOL RECEPTOR VALUES IN PRIMARY BREAST CANCER AND RESPONSE OF METASTASES TO ENDOCRINE THERAPY , 1981, The Lancet.

[6]  D. Barnes,et al.  The clinical value of multiple steroid receptor assays in breast cancer management , 1980, Cancer.

[7]  R. Rubens,et al.  Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer , 1980, Cancer.

[8]  A. Manni,et al.  Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy , 1980, Cancer.

[9]  M. Feldstein,et al.  The lack of relationship between estrogen receptor status and response to chemotherapy , 1980, Cancer.

[10]  Pitt Jl,et al.  Legionnaires' disease in South Australia. Prevalence and diagnosis. , 1980 .

[11]  A. Forrest,et al.  Oestrogen receptors and breast cancer: Current status , 1980, The British journal of surgery.

[12]  K Griffiths,et al.  RELATIONSHIP OF ŒSTROGEN-RECEPTOR STATUS TO SURVIVAL IN BREAST CANCER , 1979, The Lancet.

[13]  R. Hähnel,et al.  Prognostic value of estrogen receptors in primary breast cancer , 1979, Cancer.

[14]  W. McGuire,et al.  Androgen receptor assay with [3H]methyltrienolone (R1881) in the presence of progesterone receptors. , 1979, Endocrinology.

[15]  McGuire Wl,et al.  Hormone receptors: their role in predicting prognosis and response to endocrine therapy. , 1978, Seminars in oncology.

[16]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[17]  G. Trams,et al.  Specific binding of estradiol and dihydrotestosterone in human mammary cancers. , 1977, Cancer research.

[18]  J. Persijn,et al.  Oestrogen and androgen receptors in breast cancer and response to endocrine therapy. , 1975, British medical journal.

[19]  A. Calin.  DRUG TREATMENT OF RHEUMATOID ARTHRITIS , 1975, The Lancet.

[20]  E. Benson.  Assessment of response to treatment in advanced breast cancer. British Breast Group. , 1974, Lancet.

[21]  N. Gibbon.  CURE OF EARLY SYPHILIS. , 1963, Lancet.

[22]  G. Scatchard,et al.  THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .